Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further re Trading update

18 Oct 2017 07:00

RNS Number : 8763T
Premier Veterinary Group PLC
18 October 2017
 

PREMIER VETERINARY GROUP PLC

("PVG", the "Company" or the "Group")

 

Further re Trading update

 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 

 

 

London, UK, 18 October 2017 - Premier Veterinary Group plc (LSE: PVG) provides the following update on trading, following its previous update on 22 September 2017.

 

Update on US

 

The Board is pleased to announce that it has signed a further cooperation agreement with The Veterinary Cooperative ('TVC'). TVC is a Group Purchasing Organisation with over 3,000 member clinics.

 

The Board has decided to focus the Group's US resources in the mid-west and south-eastern states, where it has its largest presence, until such time that the changes the Group is implementing to improve sign up rates take effect and are sustained. The business will continue to service existing customers in all regions. The decision to focus the Group's resources will be reflected in a lower and slower growing cost base than previously envisaged.

 

Financing

 

As at 30 September 2017, the Group had in excess of £3 million of cash. Additional funds may be required towards the end of the current financial year. The Board is exploring a number of funding options and the directors are confident of being able to raise any additional finance required.

 

Pets on plan

 

The Group's recurring revenue streams are driven by the number of pets that are signed up to Premier Pet Care Plan ("PPCP"), a preventative healthcare programme for pets. The number of revenue generating pets on active plans for the fourth quarter of its 2017 financial year, and in the preceding four quarters was as follows:

 

000's

As at

Sept-16

As at

Dec-16

As at

Mar-17

As at

Jun-17

As at

Sept-17

United Kingdom

121

132

137

145

156

Europe

18

21

22

25

28

US

-

1

2

3

4

 

Total no. of fee generating pets on plan

 

139

 

154

 

161

 

173

 

188

 

The number of revenue generating pets on plan at the end of the financial year represents growth of 35% for the year.

 

In the United Kingdom, the number of pets on PPCP has grown by 29% on last year. The UK PPCP business is well established, cash generative and continues to see opportunities for growth from its existing customer base and new customer opportunities.

 

In Europe, the number of pets on PPCP at 30 September 2017 has grown by 56% on last year. Our most significant territory in Europe is the Netherlands. PPCP is branded as Huisdieren Zorg Plan ("HZP") in the Netherlands. The number of pets on HZP has grown by 46% in the last year to 24,000 pets on PPCP at 30 September 2017. HZP is expected to become profitable in the financial year ending 30 September 2018.

 

 

For further information, please contact:

 

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

Will Evans, Chief Financial Officer

 

 

Note to Editors:

 

PVG's services to third party veterinary practices, through its wholly-owned subsidiary, Premier Vet Alliance Limited ("PVA"), include the administration and support of a preventative healthcare programme for pets branded "Premier Pet Care Plan" ("PPCP"). In the US, where veterinary practices are known as veterinary hospitals, PPCP is marketed through the Company's wholly-owned subsidiary, Premier Vet Alliance (US) Limited.

 

PPCP is a structured, preventative healthcare programme for cats, dogs and rabbits and is available only through veterinary practices/hospitals. The programme is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

 

PPCP uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed 

more quickly and not given a chance to advance. What truly sets PPCP apart is its unique approach of offering an end-to-end solution and support to the practice/hospital, which has been proven to work extremely well. PVA works alongside practices/hospitals to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice/hospital performance.

 

 

For further details:

http://www.premiervetgroup.co.uk/

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward- looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors readers are cautioned not to rely on any forward-looking statement.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFFMFWWFWSESS
Date   Source Headline
21st Jul 201010:54 amRNSForm 8.5 (EPT/NON-RI)
20th Jul 201011:35 amRNSForm 8.5 (EPT/NON-RI)
20th Jul 201011:00 amRNSForm 8.5 (EPT/RI)
20th Jul 201010:46 amRNSForm 8.3 - [Ark Therapeutics]
19th Jul 201011:39 amRNSForm 8.5 (EPT/RI)
19th Jul 201011:33 amRNSForm 8.5 (EPT/RI)- Amendment 15/07
19th Jul 201011:26 amRNSForm 8.3 - Ark Therapeutics
16th Jul 201012:07 pmRNSForm 8.5 (EPT/RI)
15th Jul 20101:06 pmRNSForm 8.3 - Ark Therapeutics Group PLC
13th Jul 20107:00 amRNSARK UPDATE AND BOARD CHANGES
9th Jul 201010:16 amRNSForm 8.3 - Ark Therapeutics Group PLC - Amendment
8th Jul 201010:27 amRNSForm 8.3 - Ark Therapeutics Group PLC
7th Jul 20101:54 pmPRNForm 8.3 - Ark Therapeutic Group Plc
7th Jul 201011:50 amRNSForm 8.5 (EPT/NON-RI)
6th Jul 20102:49 pmPRNForm 8.3 - Ark Therapeutics Groups Plc
6th Jul 201011:36 amRNSForm 8.5 (EPT/NON-RI)
2nd Jul 20102:15 pmPRNForm 8.3 - Ark Therapeutic Group Plc
2nd Jul 201011:45 amRNSForm 8.5 (EPT/NON-RI)
1st Jul 201011:36 amRNSForm 8.5 (EPT/RI)
30th Jun 20102:45 pmPRNForm 8.3 - Ark Therapeutic Group
30th Jun 201011:45 amRNSForm 8.5 (EPT/NON-RI)
29th Jun 20103:06 pmPRNForm 8.3 - Ark Therapeutic Group Plc
25th Jun 20102:34 pmPRNForm 8.3 - Ark Therapeutics Group Plc
25th Jun 201010:52 amRNSForm 8.5 (EPT/RI)-Amendment
24th Jun 201011:39 amRNSForm 8.5 (EPT/NON-RI)
24th Jun 201010:23 amRNSForm 8.5 (EPT/RI)
23rd Jun 201011:45 amRNSForm 8.5 (EPT/NON-RI)
23rd Jun 201011:39 amRNSForm 8.5 (EPT/RI)
22nd Jun 20102:50 pmPRNForm 8.3 - Ark Therapeutics
22nd Jun 201011:41 amRNSForm 8.5 (EPT/RI)
21st Jun 20102:48 pmRNSForm 8.3 - Ark Therapeutics Group plc
21st Jun 20102:07 pmPRNForm 8.3 - ARK THERAPEUTIC PLC
21st Jun 20101:16 pmRNSForm 8.3 - Ark Therapeutics Plc
21st Jun 201010:48 amRNSForm 8.5 (EPT/RI)
18th Jun 20102:33 pmPRNForm 8.3 - Ark Therapeutics Group Plc
18th Jun 201012:19 pmRNSForm 8.3 - Ark Therapeutics Plc
18th Jun 201011:45 amRNSForm 8.5 (EPT/NON-RI)
18th Jun 201011:02 amRNSHolding(s) in Company
17th Jun 20102:42 pmPRNForm 8.3 - Ark Therapeutics Group
17th Jun 20102:41 pmRNSForm 8.3 - Ark Therapeutics Group PLC
17th Jun 20101:47 pmRNSForm 8.3 - Ark Therapeutics Plc
17th Jun 201011:32 amRNSForm 8.5 (EPT/NON-RI)
16th Jun 201011:25 amRNSForm 8.5 (EPT/RI)
16th Jun 20109:19 amRNSForm 8.5 (EPT/NON-RI)
15th Jun 20103:12 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Jun 20102:43 pmPRNForm 8.3 - Ark Therapeutics Group Plc
15th Jun 201012:38 pmRNSForm 8.3 - Ark Therapeutics Plc
15th Jun 20109:47 amRNSForm 8.5 (EPT/NON-RI)
14th Jun 20103:08 pmRNSForm 8.3 - Ark Therapeutics Group PLC
14th Jun 20101:30 pmRNSForm 8.3 - Ark Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.